Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BETA-2 vs VOSOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing c AMP, leading to bronchodilation and inhibition of mast cell mediator release.
Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.
FDA-approved: Treatment of asthma (acute bronchospasm and prophylaxis), COPD exacerbations,Off-label: Preterm labor tocolysis, hyperkalemia
Treatment of superficial bacterial infections of the external auditory canal,Treatment of seborrheic dermatitis of the ear
2.5 mg via nebulization every 4-6 hours as needed for bronchospasm; or 90 mcg (2 inhalations) via metered-dose inhaler every 4-6 hours.
Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.
Terminal elimination half-life of 3-6 hours; clinical context: requires frequent dosing (every 4-6 hours) for sustained bronchodilation.
Terminal elimination half-life: 2–4 hours. Clinical context: Short half-life necessitates frequent dosing for sustained effect; prolonged in renal impairment.
Metabolized by catechol-O-methyltransferase (COMT), monoamine oxidase (MAO), and sulfate conjugation in the gastrointestinal tract and liver.
Acetic acid is metabolized via the Krebs cycle; hydrocortisone is hepatically metabolized primarily by CYP3A4.
Primarily renal excretion of unchanged drug and sulfate conjugates; 60-70% as unchanged drug, 15-20% as sulfate metabolites, minor biliary/fecal elimination (<5%).
Renal: 95% as unchanged drug and metabolites; biliary/fecal: <5%.
50-60% bound to albumin.
90–95%, primarily to albumin.
4-5 L/kg (large Vd indicating extensive tissue distribution, particularly lung tissue).
Vd: 0.3–0.5 L/kg; clinical meaning: moderate distribution into total body water, limited tissue penetration.
Inhalation: 10-20% (due to deposition and first-pass metabolism from swallowed portion). Oral: 40-50% (significant first-pass metabolism to sulfate conjugates).
Otic: 80–90% (local absorption with minimal systemic).
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, reduce dose by 50% and monitor for systemic effects.
No dosage adjustment required for renal impairment.
No specific Child-Pugh-based adjustments; caution in severe hepatic impairment due to reduced clearance; consider dose reduction of 50% in Child-Pugh Class C.
No dosage adjustment required for hepatic impairment.
0.15 mg/kg/dose (max 5 mg) via nebulization every 4-6 hours; or 1-2 inhalations (90 mcg each) via MDI every 4-6 hours as needed.
Children: Instill 3 drops into the affected ear(s) 3-4 times daily; use as directed by physician.
Use lowest effective dose; potential for increased cardiovascular sensitivity; consider starting at 1.25 mg nebulization or 1 inhalation every 6 hours, titrate cautiously.
No specific geriatric dosage adjustment; use same as adult dosing with caution for increased sensitivity.
Increased risk of asthma-related death with beta-2 agonists; use inhaled beta-2 agonists alone for asthma is not recommended without concomitant inhaled corticosteroid.
None
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension, arrhythmias), hypokalemia, hyperglycemia, immediate hypersensitivity reactions, and worsening of asthma symptoms.
For external use only,Not for use in eyes,Discontinue if irritation or sensitization occurs,Prolonged use may result in overgrowth of non-susceptible organisms,Use caution in perforated tympanic membrane
Hypersensitivity to beta-2 agonists or any component of the formulation; use in patients with tachyarrhythmias (e.g., atrial fibrillation with rapid ventricular response) unless benefit outweighs risk.
Hypersensitivity to any component,Viral infections of the ear (e.g., herpes simplex, varicella),Fungal infections unless treated with concomitant antifungal therapy
No significant food interactions. Avoid caffeine-containing foods and beverages if experiencing palpitations or tremors. Maintain adequate potassium intake as beta-2 agonists can cause hypokalemia.
No known food interactions. Alcohol consumption is not restricted.
FDA Pregnancy Category C. First trimester: Insufficient human data; animal studies show teratogenicity at high doses. Second/third trimester: Risk of fetal tachycardia, hypoglycemia, and intrauterine growth restriction due to beta-2 receptor stimulation. Prolonged use may delay labor.
VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged systemic use may increase risk of orofacial clefts (first trimester) and fetal adrenal suppression. Acetic acid is considered low risk. Second/third trimester: minimal systemic absorption from otic use, but theoretical risk of adrenal suppression with high doses.
Excreted into breast milk in low amounts; M/P ratio estimated at 0.8 (range 0.5-1.2). Considered compatible with breastfeeding; monitor infant for signs of stimulation (e.g., tachycardia, irritability).
No data on excretion in human milk; topical otic use likely results in negligible systemic absorption. Use caution. M/P ratio unknown.
No routine dose adjustment required. Increased clearance in pregnancy may necessitate higher doses for bronchodilation; monitor clinical response. For tocolysis, use lowest effective dose and limit duration to 48-72 hours due to maternal-fetal risks.
No dosing adjustments required for topical otic use due to minimal systemic absorption; use standard dose (5 drops in affected ear(s) 3-4 times daily). Avoid prolonged use (>10 days) to minimize potential systemic effects.
Beta-2 agonists (e.g., albuterol, salmeterol) are primarily used for bronchodilation in asthma and COPD. Short-acting beta-2 agonists (SABAs) are first-line for acute symptoms, while long-acting beta-2 agonists (LABAs) are maintenance therapy, never as monotherapy in asthma. Monitor for hypokalemia and tachycardia. Use with caution in patients with cardiovascular disease, hyperthyroidism, or diabetes. Inhaled route minimizes systemic effects. Overuse indicates poor disease control.
VOSOL HC contains acetic acid (2%) and hydrocortisone (1%) in a propylene glycol vehicle. It is indicated for the treatment of otitis externa (swimmer's ear), particularly when inflammation is present. The acetic acid lowers the p H to ~3-4, creating an unfavorable environment for bacteria and fungi. Hydrocortisone reduces inflammation and pruritus. Do not use in patients with a perforated tympanic membrane (risk of ototoxicity). The solution should be instilled with the patient's head tilted to the side, and the tragus massaged to facilitate penetration. Use the dropper provided; do not allow the dropper tip to contact the ear canal to avoid contamination. Duration of therapy typically 7-10 days.
Use only as prescribed; do not increase frequency or dose without consulting your doctor.,Rinse mouth with water after using inhalers containing corticosteroids to prevent thrush.,Seek emergency help if symptoms worsen or if you need more than 2 puffs per week of rescue inhaler.,Know the difference between rescue (blue) and controller (usually brown/purple) inhalers.,Shake inhaler well before use and use proper technique (spacer if needed).,Report palpitations, chest pain, or severe anxiety to your healthcare provider.,Do not stop controller medication suddenly as it may cause worsening of symptoms.
Instill 5 drops into the affected ear(s) 3-4 times daily for 7-10 days.,Keep the dropper tip clean; do not touch the tip to any surface, including the ear.,Tilt head sideways and stay in that position for 5 minutes after instilling drops.,Do not use if you have a punctured eardrum or ear tubes.,Notify your doctor if symptoms persist after 7 days or worsen.,This medication contains benzalkonium chloride (preservative) and propylene glycol; may cause contact dermatitis in sensitive individuals.,Avoid swimming or getting water in the ear during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BETA-2 vs VOSOL HC, answered by our medical review team.
BETA-2 is a Beta-2 Agonist that works by Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing c AMP, leading to bronchodilation and inhibition of mast cell mediator release.. VOSOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BETA-2 and VOSOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BETA-2 is: 2.5 mg via nebulization every 4-6 hours as needed for bronchospasm; or 90 mcg (2 inhalations) via metered-dose inhaler every 4-6 hours.. The standard adult dose of VOSOL HC is: Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BETA-2 and VOSOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BETA-2 is classified as Category C. FDA Pregnancy Category C. First trimester: Insufficient human data; animal studies show teratogenicity at high doses. Second/third trimester: Risk of fetal tachycardia, hypoglycemi. VOSOL HC is classified as Category C. VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.